Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tamara Maule

Optometrist, Corneal and Contact Management Boca Raton, FL Doctor of Optometry

NPI 1063409019 CMS profile 2167

8903 Glades Rd, Bay A 1, Boca Raton, FL 33434

Open in the dashboard

General payments

$11,619

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tamara Maule of Boca Raton, FL is reported in the CMS Open Payments database as having received $11,619 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Optometrist, Corneal and Contact Management profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,262 15
2024 General $1,241 21
2023 General $4,682 23
2022 General $838 13
2021 General $1,385 14
2020 General $792 11
2019 General $1,419 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tamara Maule
  • Optometrist, Corneal and Contact Management median
  • Middle half of Optometrist, Corneal and Contact Management
  • National median

In program year 2025, general payments to Tamara Maule were reported at $1,262. Among 618 Optometrist, Corneal and Contact Management profiles paid that year, the median was $227 and the middle half received between $95 and $604.

Show as a table
Year Tamara Maule Optometrist, Corneal and Contact Management median Middle half National median
2019 $1,419 $203 $84–$530 $163
2020 $792 $88 $35–$234 $114
2021 $1,385 $143 $54–$353 $132
2022 $838 $167 $65–$422 $149
2023 $4,682 $195 $76–$549 $160
2024 $1,241 $202 $85–$523 $164
2025 $1,262 $227 $95–$604 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $4,603 20 payments
  2. Alcon Vision LLC $1,618 36 payments
  3. CooperVision Inc. $1,293 15 payments
  4. Allergan Inc. $795 3 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $646 7 payments
  6. Johnson & Johnson Vision Care, Inc. $631 9 payments
  7. Optos, Inc. $459 5 payments
  8. Sun Pharmaceutical Industries Inc. $416 5 payments
  9. LKC Technologies, Inc. $146 2 payments
  10. Sight Sciences, Inc. $135 1 payment
  11. Other $877 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,389 109 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,000 1 payment
  3. Consulting Fee $650 1 payment
  4. Travel and Lodging $357 1 payment
  5. Entertainment $206 2 payments
  6. Gift $17 1 payment
Products named General payments · program years 2019–2025
  1. INFUSE $1,119 14 payments
  2. CVI Contact Lens $843 10 payments
  3. Precision 1 $667 17 payments
  4. ULTRA $473 5 payments
  5. Acuvue $464 4 payments
  6. DAILIES $428 8 payments
  7. BIOTRUE ONE DAY $403 5 payments
  8. Cequa $371 4 payments
  9. Xelpros $371 4 payments
  10. OCT OPHTHALMOSCOPE $361 4 payments
  11. Other $5,084 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$17,396

Medicare's payments for the services billed

Medicare patients

184

Average age 76

Services billed

199

102 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 45%
Ischemic heart disease 38%
Diabetes 24%
Chronic kidney disease 22%
Depression 22%
Osteoporosis 22%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist, Corneal and Contact Management in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record